Fresenius’ HighVolumeHDF shows benefits for dialysis patients

Fresenius Medical Care has highlighted data from a recent study that demonstrates the benefits of its haemodiafiltration (HDF) therapy offering HighVolumeHDF.

Results from the Catalonian Online Haemodiafiltration Survival Study revealed that haemodiafiltration therapy with high volumes of substitution fluid can significantly improve patient survival compared with conventional dialysis treatment.

A 30 percent reduced risk of all-cause mortality for patients treated with HDF was observed in the trial, which involved 906 patients from 27 centres in Spain's Catalonia region and represented the largest study to date on HDF.

Professor Bernard Canaud, chairman of Fresenius Medical Care's medical board for Europe, the Middle East, Africa and Latin America, said: "HighVolumeHDF significantly improves patient survival and quality of life versus standard haemodialysis and should therefore be the standard in cardioprotective haemodialysis for all patients."

Earlier this month, the Fresenius group announced that it expects to achieve a new sales and earnings record in 2013, with revenues expected to exceed 20 billion euros (17.01 billion pounds).